drugset
Drugs / VXA-A1.1
last change Jan 2018 re-read 2 minutes ago

VXA-A1.1

also known as Ad-HA-dsRNA (VXA-A1.1)

Vaccine

Developed for
influenza
Investigated by
Vaxart · Biomedical Advanced Research and Development Authority

Trials 3 · a red edge is where a trial was stopped

today NCT02918006 · Ph 2 NCT01761123 · Ph 1 NCT01688297 · Ph 1
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01761123 Jan 2013 → Oct 2014 influenza Vaxart Completed No outcome recorded
Phase 1 NCT01688297 Sep 2012 → May 2014 influenza Vaxart Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02918006 Aug 2016 → Aug 2017 influenza Vaxart Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as VXA-A1.1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01688297 ↗
2

NCT02918006 ↗

NCT01761123 ↗
Known as Ad-HA-dsRNA (VXA-A1.1) “Ad-HA-dsRNA (VXA-A1.1)” NCT01688297 ↗
Modality Vaccine “oral tablet vaccine against influenza A H1N1” PMID 26333337 ↗ Sep 2015
Route Oral “delivered orally by tablets” PMID 26333337 ↗ Sep 2015